List view / Grid view
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-300x278.jpg)
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-e1653043421551.jpg)
Capabilities include the latest in sterile lyophilisation and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends.
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2.
The East Syracuse site will serve as the LOTTE Centre for North America Operations for LOTTE’s new biologics contract development and manufacturing organisation (CDMO) business in the United States.
The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
Combining Sarclisa® (isatuximab) with carfilzomib and dexamethasone (Kd) resulted in more than three years of progression free survival for relapsed multiple myeloma patients.
A new study published in the Journal of Controlled Release reports some intriguing developments in the tumour-targeting delivery of nanomedicines.
The Phase III MANDALA trial has demonstrated that the combination medication PT027 significantly reduces the risk of severe exacerbation in patients with moderate to severe asthma, reports AstraZeneca.
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide (CGRP) programmes, including migraine treatment rimegepant.
New research may expand the applications of terahertz (THz) imaging technology in biomedical sensing and chemical inspection.
Phase I trial data suggests that a vaccine targeting three mosquito-borne encephalitis viruses is safe and can elicit an immune response.
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-300x278.jpg)
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-e1652444508201.jpg)
Roche shares initiative commitments that will extend prophylactic treatment access to patients with haemophilia, as well as investments to provide testing capabilities for HIV and Tuberculosis in developing countries.
It seems that sprinkles, commonly known as hundreds and thousands, have undersold their capabilities, as a US scientist identifies their application could uniquely identify billions of individual tablets, potentially thwarting industry fraud.
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
Northwestern Medicine scientists have identified a drug, abemaciclib, that inhibits growth of the most aggressive meningiomas and identified a way to predict recurrence more accurately.
